2,4-Dihydroxybenzaldehyde
Based on 1 Customer Validation
2,4-Dihydroxybenzaldehyde is an endogenous metabolite. 2,4-Dihydroxybenzaldehyde is a pharmaceutical intermediate that can be used to synthesize various Schiff base compounds. 2,4-Dihydroxybenzaldehyde exhibits significant anti angiogenic, anti-inflammatory, and analgesic activities. 2,4-Dihydroxybenzaldehyde reduces the production of NO and ROS by inhibiting the expression of iNOS and COX-2. 2,4-Dihydroxybenzaldehyde is commonly used in the study of inflammatory conditions.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.90%
- No. CAS: 95-01-2
- Fòrmula: C7H6O3
- Peso molecular:138.12
-
Almacenamiento:
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-N0295
ProtocatechualdehydePolyphenol Compound -
HY-N1673
2,5-DihydroxybenzaldehydeAntimicrobial Agent -
HY-76006
3-HydroxybenzaldehydeSubstrate For ALDH, Precursor Compound for Phenolic Compounds -
HY-N1096
VeratraldehydeAromatic Compound -
HY-W007539R
2,4-Dihydroxybenzaldehyde (Standard)Drug Intermediate -
HY-N0295R
Protocatechualdehyde (Standard)Polyphenol Compound -
HY-N0098
VanillinPhenolic Aldehyde -
HY-N1390
SyringaldehydeCOX-2 Inhibitor -
HY-W007454
2-NitrobenzaldehydeBiochemical Reagent -
HY-Y0785
Glyoxal (40% w/w in water)Drug Intermediate -
HY-N0098R
Vanillin (Standard) -
HY-W001138
4-BromobenzaldehydeBiochemical Reagent
Ver todos los productos específicos de isoformas Endogenous Metabolite
More
Actividad biológica
Descripciòn
IC50 & Target
[2]|
Human Endogenous Metabolite |
iNOS |
COX-2 |
In Vitro
2,4-Dihydroxybenzaldehyde (0-0.1 mM, 24 h) significantly inhibits LPS (HY-D1056) induced NO production in a dose-dependent manner in RAW264.7 cells[2].
2,4-Dihydroxybenzaldehyde (0-0.1 mM, 24 h) inhibits LPS induced iNOS and COX-2 protein expression in a dose-dependent manner in RAW264.7 cells[2].
2,4-Dihydroxybenzaldehyde (0-0.05 mM, 24 h) can slightly reduce the increase in ROS levels caused by LPS in RAW264.7 cells[2].
2,4-Dihydroxybenzaldehyde (0-0.1 mM, 24 h) is non-toxic to RAW264.7 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:RAW264.7 cells
-
Concentration:0, 0.02, 0.05 and 0.1 mM
-
Incubation Time:24 h
-
Result:Significantly reduced the levels of iNOS and COX-2.
In Vivo
2,4-Dihydroxybenzaldehyde (0.03-0.3 mg/pouch, directly inject the airbag, single dose) significantly reduces exudate volume, neutrophil count, and nitrite content in rats with a λ-carrageenan (HY-N9470)-induced air pouch formation[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Acetic acid induced male ICR mice (4 weeks, 25 g)[2]
-
Dosage:10, 30 and 100 mg/kg
-
Administration:Oral administration (p.o.), single dose
-
Result:Had an inhibitory effect on vascular permeability at 10 mg/kg (inhibition rate 16.7%), 30 mg/kg (inhibition rate 27.9%) and 100 mg/kg (inhibition rate 45.2%).
Significantly reduced the number of twisting events.
Chemical Information
-
No. CAS 95-01-2
-
Appearance Solid
-
Peso molecular 138.12
-
Fòrmula C7H6O3
-
Color White to yellow
-
SMILES
O=CC1=CC=C(O)C=C1O
-
Structure Classification
-
Initial Source
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Solvente y solubilidad
In Vitro:
DMSO : 100 mg/mL (724.01 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (18.10 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (18.10 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocolo
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Pureza y Documentación
-
Ficha de datos (285 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 7.2401 mL | 36.2004 mL | 72.4008 mL | 181.0020 mL |
| 5 mM | 1.4480 mL | 7.2401 mL | 14.4802 mL | 36.2004 mL | |
| 10 mM | 0.7240 mL | 3.6200 mL | 7.2401 mL | 18.1002 mL | |
| 15 mM | 0.4827 mL | 2.4134 mL | 4.8267 mL | 12.0668 mL | |
| 20 mM | 0.3620 mL | 1.8100 mL | 3.6200 mL | 9.0501 mL | |
| 25 mM | 0.2896 mL | 1.4480 mL | 2.8960 mL | 7.2401 mL | |
| 30 mM | 0.2413 mL | 1.2067 mL | 2.4134 mL | 6.0334 mL | |
| 40 mM | 0.1810 mL | 0.9050 mL | 1.8100 mL | 4.5251 mL | |
| 50 mM | 0.1448 mL | 0.7240 mL | 1.4480 mL | 3.6200 mL | |
| 60 mM | 0.1207 mL | 0.6033 mL | 1.2067 mL | 3.0167 mL | |
| 80 mM | 0.0905 mL | 0.4525 mL | 0.9050 mL | 2.2625 mL | |
| 100 mM | 0.0724 mL | 0.3620 mL | 0.7240 mL | 1.8100 mL |
2,4-Dihydroxybenzaldehyde Related Classifications
HY-W007539 Related Classifications
Powered by Bioz